{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:42:11Z","timestamp":1789756931717,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction and Hypothesis<\/jats:title>\n                    <jats:p>Whether treatment setting impacts periurethral bulking efficacy is unknown. We hypothesized that periurethral bulking treatment failure rates would be greater for office versus operating room procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study including 113 patients undergoing polyacrylamide hydrogel periurethral bulking at a single academic medical center between 1 September 2022 and 30 March 2024 was carried out. Demographic and clinical variables, procedural details, patient satisfaction, and retreatment rates were abstracted. Primary outcomes included 6-month treatment failure, defined as no improvement following treatment, decision for additional therapy, or aborted procedure. Secondary outcomes included 12-month treatment failure and 6- and 12-month retreatment rates. Chi-squared, Fisher\u2019s exact, Mann\u2013Whitney\n                      <jats:italic>U<\/jats:italic>\n                      , and\n                      <jats:italic>t<\/jats:italic>\n                      tests were applied, and logistic regression was used to identify factors associated with treatment failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 6- and 12-month treatment failure rates in the operating room versus office cohorts were 32.4% vs 51.3% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05) and 48.1% vs 50.0% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.87) respectively. Retreatment rates and modality did not differ. Approximately 15% of office cases but no operating room cases were unable to be completed as planned (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Office setting was associated with 3.23 increased odds of 6-month treatment failure (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Periurethral bulking in the office may be more likely to result in early treatment failure than bulking performed in the operating room, but any benefit appears short lived, with similar 12-month treatment failure and retreatment rates. Our findings, together with consideration of individual patient characteristics and resource optimization, can guide decisions regarding the appropriate treatment setting for periurethral bulking.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00192-025-06236-5","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T12:27:15Z","timestamp":1758371235000},"page":"469-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Treatment Setting on Periurethral Bulking"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7606-9316","authenticated-orcid":false,"given":"Erin E.","family":"Mowers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Ackenbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Giugale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Artsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"6236_CR1","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1056\/NEJMcp1914037","volume":"384","author":"JM Wu","year":"2021","unstructured":"Wu JM. Stress incontinence in women. N Engl J Med. 2021;384:2428\u201336. https:\/\/doi.org\/10.1056\/NEJMcp1914037.","journal-title":"N Engl J Med"},{"key":"6236_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/AOG.0000000000000286","volume":"123","author":"JM Wu","year":"2014","unstructured":"Wu JM, Matthews CA, Conover MM, Pate V, Funk MJ. Lifetime risk of stress incontinence or pelvic organ prolapse surgery. Obstet Gynecol. 2014;123:1201\u20136. https:\/\/doi.org\/10.1097\/AOG.0000000000000286.","journal-title":"Obstet Gynecol"},{"key":"6236_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11934-022-01099-5","volume":"23","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Rovner E. Update on urethral bulking for stress urinary incontinence in women. Curr Urol Rep. 2022;23:203\u20139. https:\/\/doi.org\/10.1007\/s11934-022-01099-5.","journal-title":"Curr Urol Rep"},{"key":"6236_CR4","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/nau.24696","volume":"40","author":"V Hoe","year":"2021","unstructured":"Hoe V, Haller B, Yao HH, O\u2019Connell HE. Urethral bulking agents for the treatment of stress urinary incontinence in women: a systematic review. Neurourol Urodyn. 2021;40:1349\u201388. https:\/\/doi.org\/10.1002\/nau.24696.","journal-title":"Neurourol Urodyn"},{"key":"6236_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00192-021-04891-y","volume":"33","author":"SS Myhr","year":"2022","unstructured":"Myhr SS, Rakovan M, Schi\u00f8tz HA. Periurethral injection with polyacrylamide after previous TVT surgery. Int Urogynecol J. 2022;33:1017\u201322. https:\/\/doi.org\/10.1007\/s00192-021-04891-y.","journal-title":"Int Urogynecol J"},{"key":"6236_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.maturitas.2022.05.007","volume":"163","author":"A Braga","year":"2022","unstructured":"Braga A, Caccia G, Papadia A, Treglia G, Castronovo F, Salvatore S, et al. Urethral bulking agents for the treatment of recurrent stress urinary incontinence: a systematic review and meta-analysis. Maturitas. 2022;163:28\u201337. https:\/\/doi.org\/10.1016\/j.maturitas.2022.05.007.","journal-title":"Maturitas"},{"key":"6236_CR7","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3390\/jcm11061569","volume":"11","author":"A Giamm\u00f2","year":"2022","unstructured":"Giamm\u00f2 A, Geretto P, Ammirati E, Manassero A, Squintone L, Falcone M, et al. Urethral bulking in the treatment of stress and mixed female urinary incontinence: results from a multicenter cohort and predictors of clinical outcomes. J Clin Med. 2022;11:1569. https:\/\/doi.org\/10.3390\/jcm11061569.","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"6236_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/bju.15717","volume":"130","author":"V Hoe","year":"2022","unstructured":"Hoe V, Yao HH, Gough K, O\u2019Connell HE. Long-term outcomes of polyacrylamide hydrogel treatment in women with stress urinary incontinence. BJU Int. 2022;130(Suppl 1):22\u20134. https:\/\/doi.org\/10.1111\/bju.15717.","journal-title":"BJU Int"},{"key":"6236_CR9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/nau.24388","volume":"39","author":"A Giamm\u00f2","year":"2020","unstructured":"Giamm\u00f2 A, Geretto P, Ammirati E, Manassero A, Squintone L, Vercelli D, et al. Urethral bulking with Bulkamid: an analysis of efficacy, safety profile, and predictors of functional outcomes in a single-center cohort. Neurourol Urodyn. 2020;39:1523\u20138. https:\/\/doi.org\/10.1002\/nau.24388.","journal-title":"Neurourol Urodyn"},{"key":"6236_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00192-010-1214-1","volume":"21","author":"G Lose","year":"2010","unstructured":"Lose G, S\u00f8rensen HC, Axelsen SM, Falconer C, Lobodasch K, Safwat T. An open multicenter study of polyacrylamide hydrogel (Bulkamid\u00ae) for female stress and mixed urinary incontinence. Int Urogynecol J. 2010;21:1471\u20137. https:\/\/doi.org\/10.1007\/s00192-010-1214-1.","journal-title":"Int Urogynecol J"},{"key":"6236_CR11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/nau.24589","volume":"40","author":"T Brosche","year":"2021","unstructured":"Brosche T, Kuhn A, Lobodasch K, Sokol ER. Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence. Neurourol Urodyn. 2021;40:502\u20138. https:\/\/doi.org\/10.1002\/nau.24589.","journal-title":"Neurourol Urodyn"},{"key":"6236_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00192-015-2781-y","volume":"27","author":"AD Kasi","year":"2016","unstructured":"Kasi AD, Pergialiotis V, Perrea DN, Khunda A, Doumouchtsis SK. Polyacrylamide hydrogel (Bulkamid\u00ae) for stress urinary incontinence in women: a systematic review of the literature. Int Urogynecol J. 2016;27:367\u201375. https:\/\/doi.org\/10.1007\/s00192-015-2781-y.","journal-title":"Int Urogynecol J"},{"key":"6236_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00404-013-2718-y","volume":"288","author":"ULR Maggiore","year":"2013","unstructured":"Maggiore ULR, Alessandri F, Medica M, Gabelli M, Venturini PL, Ferrero S. Outpatient periurethral injections of polyacrylamide hydrogel for the treatment of female stress urinary incontinence: effectiveness and safety. Arch Gynecol Obstet. 2013;288:131\u20137. https:\/\/doi.org\/10.1007\/s00404-013-2718-y.","journal-title":"Arch Gynecol Obstet"},{"key":"6236_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.urology.2024.11.032","volume":"198","author":"B Faurie","year":"2025","unstructured":"Faurie B, Hascoet J, Richard C, Haudebert C, Nyangoh Timoh K, Peyronnet B. Outpatient periurethral injections of polyacrylamide hydrogel (Bulkamid) under local anesthesia in the office: a prospective single-center series. Urology. 2025;198:8\u201313. https:\/\/doi.org\/10.1016\/j.urology.2024.11.032.","journal-title":"Urology"},{"key":"6236_CR15","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296. https:\/\/doi.org\/10.1371\/journal.pmed.0040296.","journal-title":"PLoS Med"},{"key":"6236_CR16","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00192-017-3332-5","volume":"28","author":"S Mohr","year":"2017","unstructured":"Mohr S, Marthaler C, Imboden S, Monga A, Mueller MD, Kuhn A. Bulkamid (PAHG) in mixed urinary incontinence: what is the outcome? Int Urogynecol J. 2017;28:1657\u201361. https:\/\/doi.org\/10.1007\/s00192-017-3332-5.","journal-title":"Int Urogynecol J"},{"key":"6236_CR17","doi-asserted-by":"publisher","first-page":"175628722110692","DOI":"10.1177\/17562872211069265","volume":"14","author":"A Giamm\u00f2","year":"2022","unstructured":"Giamm\u00f2 A, Ammirati E, Geretto P, Manassero A, Squintone L, Falcone M, et al. Can urethral re-bulking improve the outcomes of a prior urethral bulking? Ther Adv Urol. 2022;14:17562872211069264. https:\/\/doi.org\/10.1177\/17562872211069265.","journal-title":"Ther Adv Urol"},{"key":"6236_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/JU.0000000000000176","volume":"202","author":"M Elmelund","year":"2019","unstructured":"Elmelund M, Sokol ER, Karram MM, Dmochowski R, Klarskov N. Patient characteristics that may influence the effect of urethral injection therapy for female stress urinary incontinence. J Urol. 2019;202:125\u201331. https:\/\/doi.org\/10.1097\/JU.0000000000000176.","journal-title":"J Urol"},{"key":"6236_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s00192-005-0011-8","volume":"17","author":"S Koduri","year":"2006","unstructured":"Koduri S, Goldberg RP, Kwon C, Dobrez DG, Sand PK. Factors influencing the long-term success of periurethral collagen therapy in the office. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:346\u201351. https:\/\/doi.org\/10.1007\/s00192-005-0011-8.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"6236_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/bco2.218","volume":"4","author":"V Hoe","year":"2023","unstructured":"Hoe V, Yao HH, Gough K, O\u2019Connell HE. Factors associated with polyacrylamide hydrogel outcomes in women with stress urinary incontinence. BJUI Compass. 2023;4:269\u201376. https:\/\/doi.org\/10.1002\/bco2.218.","journal-title":"BJUI Compass"},{"key":"6236_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1590\/S1677-5538.IBJU.2014.01.06","volume":"40","author":"CV-S Vecchioli-Scaldazza","year":"2014","unstructured":"Vecchioli-Scaldazza CV-S, Smaali C, Morosetti C, Azizi B, Giannubilo W, Ferrara V. Polyacrylamide hydrogel (Bulkamid\u00ae) in female patients of 80 or more years with urinary incontinence. Int Braz J Urol. 2014;40:37\u201343. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2014.01.06.","journal-title":"Int Braz J Urol"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-025-06236-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-025-06236-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-025-06236-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:03:23Z","timestamp":1773792203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-025-06236-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["6236"],"URL":"https:\/\/doi.org\/10.1007\/s00192-025-06236-5","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board study exemption was obtained from the University of Pittsburgh (IRB#: 24030014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"M.F.A. is supported by NIH National Institute on Aging (K23AG073517-01). A.M.A. is supported by NIH\/ORWH Building Interdisciplinary Research Careers in Women\u2019s Health (BIRCWH)\u00a0NIH K12HD043441.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}